KOSDAQBiotech & Pharma456070

ENCell

₩6,040▼ 0.98%2026-10-02 close

Market Cap

₩66.2B

Turnover

₩400M

Volume

60,000 shares

Shares out.

11M

PER

—

PBR

2.2×

EPS

-₩1,789

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Losses Persist as AAV, Japan Bets Take Shape

ENCell is pursuing a turnaround through AAV vector CDMO expansion, a Japan regenerative-medicine business, and the EN001 drug pipeline, even as revenue has fallen for three straight years and net losses have widened.

1
2025 revenue fell to KRW 5.26bn, the third straight annual decline, while operating loss widened to KRW 17.9bn
2
Q1-Q2 2026 quarterly revenue dropped to KRW 309mn and KRW 868mn, among the lowest levels on record
3
Net loss over the same period widened to KRW -5.26bn and KRW -7.23bn, expanding faster than the operating loss
4
A KRW 22.5bn convertible bond issued in December 2025 pushed the debt ratio up from 15.7% to 61.7%
5
Multiple new growth triggers—AAV CDMO, Japan regenerative medicine, EN001 Phase 2a—are set to be tested sequentially from H2 2026 into 2027

Business structure

ENCell is a cell and gene therapy (CGT) specialist founded in 2018 by Professor Jang Jong-wook of Samsung Seoul Hospital, who created the company while retaining his academic post, and listed on KOSDAQ in August 2024.

The business rests on two pillars—contract development and manufacturing (CDMO) and proprietary drug development—with all current revenue generated by the CDMO business. The company operates a GMP Plant No.1 inside Samsung Seoul Hospital plus GMP Plants No.2 and No.3 and a CGT R&D center in Hanam, Gyeonggi Province.

ENCell states it is the only Korean facility able to manufacture both cells and viral vectors simultaneously under one roof.

Its client roster includes global pharmaceutical majors such as Novartis and Janssen, and the company cites a track record spanning 20 client companies and 40 projects, positioning itself as the domestic CGT CDMO market leader by revenue and share.

More recently, the company has designated adeno-associated virus (AAV) vector CDMO as its next growth engine and established a dedicated sales organization for it.

Its proprietary pipeline centers on EN001, an allogeneic umbilical cord blood-derived mesenchymal stem cell therapy, with Charcot-Marie-Tooth disease (CMT) Type 1A as the lead indication being expanded into sarcopenia and Duchenne muscular dystrophy.

Effective January 2026, the company reorganized into four business units—New Drug R&BD, Advanced Regenerative Bio, CDMO, and Anti-Aging—while also expanding into tumor-infiltrating lymphocyte (TIL) therapy manufacturing with Samsung Seoul Hospital, Japan's regenerative medicine market, and stem cell-based anti-aging businesses.

Earnings trend

Quarterly revenue · Operating profit

₩1.2B-₩4.5B25Q2₩1.5B-₩3.7B25Q3₩1.4B-₩4.9B25Q4₩300M-₩4.9B26Q1₩900M-₩4.7B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩10.5B-₩11.8B2023₩7.2B-₩15.7B2024₩5.3B-₩17.9B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩1.2B	-₩4.5B	−379.9%
2025Q3	₩1.5B	-₩3.7B	−240.8%
2025Q4	₩1.4B	-₩4.9B	−342.7%
2026Q1	₩300M	-₩4.9B	−1576.4%
2026Q2	₩900M	-₩4.7B	−539.0%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2023	₩10.5B	-₩11.8B	-₩5.1B	−111.7%	−13.3%	15.7%
2024	₩7.2B	-₩15.7B	-₩15.2B	−217.5%	−31.6%	15.7%
2025	₩5.3B	-₩17.9B	-₩16.1B	−340.4%	−40.9%	61.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04

Earnings analysis

Consolidated revenue fell for three consecutive years, from KRW 10.53bn in 2023 to KRW 7.21bn in 2024 and KRW 5.26bn in 2025. Operating loss widened over the same period from KRW 11.76bn to KRW 15.68bn to KRW 17.90bn, pushing the 2025 operating margin down to -340.4%.

On a quarterly basis, revenue rose modestly to KRW 1.18bn in Q2 2025 and KRW 1.55bn in Q3 2025, before falling to KRW 1.44bn in Q4 2025 and sharply to KRW 309mn in Q1 2026, then partially recovering to KRW 868mn in Q2 2026.

By contrast, net loss attributable to owners widened even as revenue and operating loss stabilized—from roughly KRW -4.3bn to -4.9bn per quarter in the second half of 2025 to KRW -5.26bn in Q1 2026 and KRW -7.23bn in Q2 2026—suggesting that non-operating items, potentially including fair-value losses on convertible bond derivatives, played a larger role in the recent widening than operating performance itself.

Industry observers attribute the revenue weakness chiefly to delays in clients' clinical trial schedules, with analysts noting that subdued biotech investment sentiment over the past one to two years has pushed back revenue recognition on CDMO projects.

Rising R&D spending tied to EN001 pipeline progress has also weighed on the bottom line alongside declining revenue. On the balance sheet, the debt ratio jumped from 15.7% in 2023-2024 to 61.7% in 2025, reflecting external financing including a KRW 22.5bn convertible bond issued in December 2025.

Total equity rose from KRW 38.02bn in 2023 to KRW 48.17bn in 2024 before falling to KRW 39.40bn in 2025 on accumulated losses, while operating cash flow remained negative for three straight years (KRW -6.44bn, -10.10bn, -10.20bn), indicating continued cash consumption from operations.

Industry analysis

The global cell and gene therapy (CGT) market is projected to grow from roughly USD 7.47bn (KRW 9.76tn) in 2021 to about USD 55.5bn (KRW 72.53tn) by 2026, implying an estimated compound annual growth rate of 49.1%.

The global CGT CDMO market, including vector manufacturing, is forecast to reach about USD 30bn (roughly KRW 40tn) by 2030, with the Asia-Pacific region expected to grow fastest at an estimated 29% per year.

Even so, domestic CGT CDMO players have struggled to translate this potential into profitability, held back by the market's early-stage nature and funding-driven delays in client clinical trials.

Alongside ENCell, GC Cell, CHA Biotech, and Kangstem Biotech are cited as key domestic CGT CDMO competitors; GC Cell's CDMO revenue has trended down from KRW 7.7bn in 2022 to KRW 5.1bn in 2024, while CHA Biotech's US subsidiary Matica Biotechnology is expected by the company to grow contracted orders from roughly KRW 10bn last year to more than KRW 20bn this year.

Japan represents a notable opportunity given its dedicated regenerative medicine regulatory framework, with its regenerative medicine, cell therapy, and gene therapy market projected to expand from about JPY 381.9bn (roughly KRW 3.52tn) in 2025 to about JPY 850.5bn (roughly KRW 7.84tn) by 2030.

Against this backdrop, ENCell is seeking to build on its domestic CDMO track record while establishing new footholds in AAV vector manufacturing and Japan's regenerative medicine market at an early stage of these high-growth markets.

Outlook

In January 2026 the company reorganized into four business units—New Drug R&BD, Advanced Regenerative Bio, CDMO, and Anti-Aging—formally signaling its transition from a pure-play CDMO into a drug developer.

In the AAV segment, a KRW 5.7bn 'customized AAV gene therapy clinical production platform' project awarded by the Korea Research Institute of Bioscience and Biotechnology is a multi-year engagement running through 2029 that is expected to be recognized progressively as revenue, and the order backlog reportedly grew from KRW 4.0bn at end-2024 to KRW 9.1bn at the end of Q3 2025.

Company representatives have said they are in discussions with multiple firms to expand CDMO contracts in the second half of the year.

In June 2026 the company announced a joint sales partnership with US-based CGT CDMO firm Andelyn Biosciences linking North American and Asian markets, aimed at broadening its global order pipeline.

In Japan, the company obtained certification from the Ministry of Health, Labour and Welfare in May 2026 for its Hanam GMP Plant No.2 as a specified cell-processing manufacturing facility, and plans to launch a cross-border regenerative medicine business from the third quarter of 2026, initially supplying domestically manufactured cells to Japan.

On the drug pipeline side, EN001 received US FDA rare disease designation for CMT patients in February 2026, completed Phase 1b in March, and began dosing the first patient in Phase 2a in May, while the company has continued licensing discussions at global partnering events including ChinaBIO in Shanghai in April and BIO USA in July.

Independent research firm Growth Research has projected 2026 revenue could recover to about KRW 8bn based on AAV project recognition and Japan regenerative medicine contributions, though this is an external analyst estimate rather than official company guidance.

Valuation

PER

—

PBR

2.2×

ROE

-57.7%

EPS

-₩1,789

BPS

₩2,563

Dividend per share

₩0

Because ENCell has recorded net losses through the most recent four quarters, its price-to-earnings ratio is not meaningful in the conventional sense, and in such cases the market tends to rely on other yardsticks such as price-to-sales or price-to-book.

From a price-to-book perspective, the stock trades above net asset value, implying a premium to book, and whether future earnings improvement can support that premium is a key point to watch. The company currently pays no dividend, making dividend-yield-based comparisons of limited relevance.

Multi-year trends show revenue on a declining path and losses on a widening path, with the recovery of CDMO orders and the monetization of new businesses flagged as the key variables that will determine the future earnings trajectory.

As a smaller-cap biotech stock, share price volatility can be relatively pronounced given the company's float characteristics, which is also worth bearing in mind.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04

Bull factors

AAV and Global Partnership Expansion

ENCell plans to progressively recognize revenue through 2029 from a KRW 5.7bn AAV clinical production platform project awarded by the Korea Research Institute of Bioscience and Biotechnology, and its order backlog has reportedly been trending higher.

In June 2026 the company announced a joint sales partnership with US-based Andelyn Biosciences linking North American and Asian markets, broadening its overseas client discovery channel.

The company has also said additional CDMO contract discussions are underway for the second half of the year, suggesting order momentum could continue.

EN001 Clinical Progress and Rare Disease Designation

EN001 received US FDA rare disease designation for CMT patients in February 2026, completed Phase 1b in March, and began dosing the first patient in Phase 2a in May. The company is pursuing a strategy of extending the mechanism validated in CMT to broader indications such as sarcopenia.

Continued licensing discussions at global partnering events including ChinaBIO and BIO USA could widen commercialization options if further clinical data emerges.

Japan Regenerative Medicine and Anti-Aging New Business Pillars

In May 2026 ENCell obtained certification from Japan's Ministry of Health, Labour and Welfare for its Hanam GMP Plant No.2 as a specified cell-processing manufacturing facility, securing the regulatory basis for a cross-border regenerative medicine business.

Building on this, the company plans to begin supplying domestically manufactured cells to Japan from the third quarter, targeting a Japanese regenerative medicine market expected to expand through 2030.

The company is also pursuing a royalty-based aesthetics business, including anti-aging mask packs built on IP developed alongside EN001, diversifying revenue sources beyond CDMO.

Bear factors

Three Straight Years of Revenue Decline and Extremely Low Recent Quarterly Revenue

Consolidated revenue fell for three straight years from KRW 10.53bn in 2023 to KRW 5.26bn in 2025, and dropped further to KRW 309mn in Q1 2026, the lowest quarterly figure since listing. Q2 2026 revenue recovered only modestly to KRW 868mn, still below the first-half 2025 run rate of more than KRW 1.1bn per quarter.

Industry analysts attribute the weakness to clients' clinical trial delays pushing back revenue recognition, leaving the timing of order-to-revenue conversion for CDMO contracts uncertain.

Widening Net Loss and Cost Burden

Net loss attributable to owners widened from roughly KRW -3.5bn to -4.9bn per quarter in the second half of 2025 to KRW -5.26bn in Q1 2026 and KRW -7.23bn in Q2 2026.

Since the operating loss moved relatively modestly in the KRW -4.4bn to -4.9bn range over the same period, the widening in net loss may reflect greater non-operating costs, potentially including fair-value losses tied to convertible bond derivatives.

The debt ratio also jumped from 15.7% in 2024 to 61.7% in 2025, indicating growing reliance on external financing.

Sector-Wide Delay in Monetization

A common observation across the industry is that domestic CGT CDMO companies have struggled to accelerate monetization despite the market's growth potential. Competitor GC Cell's CDMO revenue also trended down from KRW 7.7bn in 2022 to KRW 5.1bn in 2024.

Meanwhile, CHA Biotech's Matica Bio has succeeded in expanding contracts centered on the US market, raising the possibility that ENCell could fall relatively behind in the global order competition.

Risk factors

Liquidity and Dilution Risk

The KRW 22.5bn convertible bond issued in December 2025 carries a conversion price of KRW 14,295 and could potentially increase shares outstanding by 12.62% upon conversion.

Bondholders can request early redemption starting December 30, 2026, twelve months after issuance, making the company's cash position around that date a key point to monitor. Given persistent operating losses and negative operating cash flow, the need for further external financing cannot be ruled out.

Client Clinical Trial and Revenue Recognition Delay Risk

Since all of ENCell's revenue comes from CDMO, financial performance is heavily dependent on clients' new drug clinical trial timelines. Subdued biotech investment sentiment over the past one to two years has repeatedly delayed client trials, pushing back CDMO revenue recognition.

While reports suggest the order backlog has been growing, the timing and pace of conversion into actual revenue remains dependent on client circumstances.

New Drug Clinical Trial Outcome Risk

EN001's Phase 2a trial compares placebo, low-dose, and high-dose groups and must confirm changes in neuropathy scores at the 24-week mark, with the key question being whether the safety and efficacy signals seen in Phase 1 are reproduced in a placebo-controlled setting.

If results fall short of expectations, this could affect licensing negotiations or the timeline for pursuing conditional approval. As with any drug development program, uncertainty around timing and outcomes persists at every clinical stage.

What to watch next

Around November 2026 (expected)
The Q3 2026 earnings disclosure will show whether revenue is recovering and how much the AAV and Japan businesses are contributing.
Q3-Q4 2026
This is the window to check whether the company's planned Japan cross-border regenerative medicine business generates its first revenue and at what initial scale.
December 30, 2026
This is the first date bondholders of the KRW 22.5bn convertible bond can request early redemption; it is worth checking whether redemption is requested and how the company manages cash accordingly.
H2 2026
Whether additional AAV/CDMO contracts referenced by the company materialize will indicate whether order momentum is sustained.
2027 (expected)
The progress of the EN001 Phase 2a trial and the timing of any data readout should be monitored continuously.

Overall view

ENCell holds a track record in Korea's CGT CDMO space, but has seen revenue decline for three straight years from 2023 through 2025, alongside widening operating and net losses.

In the first half of 2026, quarterly revenue fell to record lows, and net losses have grown faster than operating losses, adding to financial pressure.

Against this backdrop, the company has reorganized into four business units while simultaneously pursuing several new growth avenues—AAV vector CDMO, a Japan regenerative medicine cross-border business, anti-aging aesthetics, and EN001 drug development.

Concrete evidence of expansion includes the Korea Research Institute of Bioscience and Biotechnology project, the global partnership with Andelyn Biosciences, and the Japanese Ministry of Health, Labour and Welfare certification, but the timing and scale at which these translate into actual revenue and profit remain uncertain.

The rise in the debt ratio following the KRW 22.5bn convertible bond issuance, the upcoming early redemption window, and the outcome of the EN001 Phase 2a trial remain key variables that will shape the company's future earnings and financial structure.

Investors will need to continue tracking upcoming quarterly results and the pace of monetization of new businesses to assess whether the turnaround narrative is backed by actual performance.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.